Recent 8-K filings for LFCR
Highest-materiality recent filing
Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M
- Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
- FY2025 revenue $128.9M (+0.5% YoY); net loss $38.7M vs $12.0M income; adj. EBITDA $19.5M vs $20.2M.
-
Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance
Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
-
Lifecore Biomedical reports transition period revenue $75.5M (+20% y/y), Adj. EBITDA $13.1M
Revenue for seven-month transition period $75.5M, +20% vs prior comparable period; Q4 revenue $35.7M, +10% y/y.
-
Board changed fiscal year from May-ending to calendar year, effective May 26, 2025 – Dec 31, 2025.
-
Lifecore Biomedical adopts Incentive Bonus Plan for executives and key employees
Plan effective Jan 14, 2026; covers executive officers and selected employees.
-
Lifecore changes fiscal year to calendar year, effective May 26, 2025
Board approved fiscal year change on Aug 1, 2025; new calendar year ends Dec 31.
-
Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M
Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
-
Lifecore Biomedical stockholders elect nine directors and ratify KPMG at 2025 annual meeting
Katrina L. Houde, Humberto C. Antunes, Paul H. Johnson, Paul Josephs, Matthew E. Korenberg, Nelson Obus, Joshua E. Schechter elected by common and Series A holders.
-
Lifecore Biomedical approves CY 2025 transition bonus plan; CEO target 100% of base salary
New bonus plan covers the approximate seven-month transition period May 26, 2025 through Dec 31, 2025.
-
Lifecore Biomedical dismisses BDO and appoints KPMG as new independent auditor
Audit Committee approved appointment of KPMG on August 12, 2025 as independent registered public accounting firm for transition period ending December 31, 2025.
-
Filing furnishes a presentation dated August 12, 2025 for investor discussions.
-
Lifecore FY2025 revenue $128.9M meets guidance; net loss $38.7M; guides transition period $74-76M
Q4 revenue $36.4M (-4% YoY); net loss $1.1M vs $7.1M loss; adj. EBITDA $9.1M vs $10.4M.
-
Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets
Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).
-
Lifecore Biomedical increases Equity Inducement Plan by 750,000 shares to 4,250,000 total
Board of Directors amended the Equity Inducement Plan on April 11, 2025, adding 750,000 shares.
-
Lifecore Biomedical shareholders approve issuance of shares beyond 19.99% threshold
At April 10, 2025 special meeting, stockholders approved the Issuance Proposal, allowing issuance of common stock underlying Series A Preferred Stock in excess of 19.99% of outstanding common shares.
-
Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M
Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.50 · Most common event other_material